The field of theranostics is expanding rapidly due to the impact on clinical outcomes including improvement in overall survival. In addition there continues to be significant investment in theranostics by the pharmaceutical industry with favorable return-on-investment. Precision Theranostics is in line with acute and foreseeable demand in this evolutionary space for leading cancers including Prostate, Breast, Lung, Renal, Endocrine, Neuroendocrine, GI and others.  

Molecular Imaging & Therapeutics, Medical Physics, Diagnostic Radiology and Radiation Oncology have traditionally been the cornerstones of Theranostics. In the past several years, Data Science/AI, Pathology and Equity have become essential in any mission where Theranostics could be considered precise. 

Precision Theranostics is founded on the notion that these developments confer a greater ability to individualize the approaches to treatment in a much more diverse patient demographic.